Will this drug be the first treatment for NASH?
There has been some success in a clinical trial but specialists flag safety issues
10th December 2019
By Clare Pain
Interim results from a clinical trial of obeticholic acid for non-alcoholic steatohepatitis (NASH) show it significantly reduces fibrosis and will probably confer clinical benefit, international researchers report.
The trial, known as REGENERATE, is the first phase-3 trial of a drug for NASH to show a positive effect, the authors say.
More than 900 patients, across 20 countries, with NASH and F2 or F3 stage fibrosis — as defined by the NASH Clinical Research Network — were randomly allocated to three trial arms, comprising once-daily
